Integrated waveguide and nanostructured sensor platform for surface-enhanced Raman spectroscopy

Limitations of current sensors include large dimensions, sometimes limited sensitivity and inherent single-parameter measurement capability. Surface-enhanced Raman spectroscopy can be utilized for environment and pharmaceutical applications with the intensity of the Raman scattering enhanced by a factor of 106. By fabricating and characterizing an integrated optical waveguide beneath a nanostructured precious metal coated surface a new surface-enhanced Raman spectroscopy sensing arrangement can be achieved. Nanostructured sensors can provide both multiparameter and high-resolution sensing. Using the slab waveguide core to interrogate the nanostructures at the base allows for the emission to reach discrete sensing areas effectively and should provide ideal parameters for maximum Raman interactions. Thin slab waveguide films of silicon oxynitride were etched and gold coated to create localized nanostructured sensing areas of various pitch, diameter, and shape. These were interrogated using a Ti:Sapphire laser tuned to 785-nm end coupled into the slab waveguide. The nanostructured sensors vertically projected a Raman signal, which was used to actively detect a thin layer of benzyl mercaptan attached to the sensors

Bayesian hierarchical model for the prediction of football results

The problem of modelling football data has become increasingly popular in the last few years and many different models have been proposed with the aim of estimating the characteristics that bring a team to lose or win a game, or to predict the score of a particular match. We propose a Bayesian hierarchical model to fulfil both these aims and test its predictive strength based on data about the Italian Serie A 1991-1992 championship. To overcome the issue of overshrinkage produced by the Bayesian hierarchical model, we specify a more complex mixture model that results in a better fit to the observed data. We test its performance using an example of the Italian Serie A 2007-2008 championship

Relief of Residual Stress in Streamline Tie Rods by Heat Treatment

About two-thirds of the residual stress in cold-worked SAE 1050 steel tie rods was relieved by heating 30 minutes at 600 degrees Fahrenheit. Cold-worked austenitic stainless-steel tie rods could be heated at temperatures up to 1000 degrees Fahrenheit without lowering the important physical properties. The corrosion resistance, in laboratory corrosion test, of straight 18:8 and titanium-treated 18:8 materials appeared to be impaired after heating at temperatures above 800 degrees or 900 degrees fahrenheit. Columbium-treated and molybdenum-treated 18:8 steel exhibited improved stability over a wide range of temperatures. Tie rods of either material could be heated 30 minutes with safety at any temperature up to 1000 degrees Fahrenheit. At this temperature most of the residual stress would be relieved

Is subdiffusional transport slower than normal?

We consider anomalous non-Markovian transport of Brownian particles in viscoelastic fluid-like media with very large but finite macroscopic viscosity under the influence of a constant force field F. The viscoelastic properties of the medium are characterized by a power-law viscoelastic memory kernel which ultra slow decays in time on the time scale \tau of strong viscoelastic correlations. The subdiffusive transport regime emerges transiently for t<\tau. However, the transport becomes asymptotically normal for t>>\tau. It is shown that even though transiently the mean displacement and the variance both scale sublinearly, i.e. anomalously slow, in time, ~ F t^\alpha, ~ t^\alpha, 0<\alpha<1, the mean displacement at each instant of time is nevertheless always larger than one obtained for normal transport in a purely viscous medium with the same macroscopic viscosity obtained in the Markovian approximation. This can have profound implications for the subdiffusive transport in biological cells as the notion of "ultra-slowness" can be misleading in the context of anomalous diffusion-limited transport and reaction processes occurring on nano- and mesoscales

USING A NONLINEAR CROSSED RANDOM EFFECTS MODEL WITH THREE-WAY TREATMENT STRUCTURE FOR DESCRIBING CIRCADIAN PATTERNS OF SERUM PROLACTIN CONCENTRATIONS IN HEAT STRESSED HOLSTEINS

A modified Gaussian model with three-level crossed and nested random effects is used to describe circadian patterns of serum prolactin concentrations in a crossover experiment. Testing of three-way treatment effects and carryover effects are incorporated with the model building process as is the within-group correlation. We found that the interaction between environment and parity had significant effect (p\u3c0.05) on both initial serum prolactin concentration and range of the prolactin concentration. There was no significant effect of recombinant bovine somatotropin (rbST) on either the initial value or concentration of serum prolactin. The inclusion of carryover effects in the model significantly improves the fit of the multilevel nonlinear mixed effects model. We present in detail a general approach to nonlinear crossed random effects model building and three-way treatment effects testing

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cost effectiveness of the technology, based upon the company's submission to NICE. The evidence was derived mainly from a randomised, double-blind, phase III, placebo-controlled trial of rivaroxaban (either 2.5 or 5 mg twice daily) in patients with recent ACS [unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI)]. In addition, all patients received antiplatelet therapy [aspirin alone or aspirin and a thienopyridine either as clopidogrel (approximately 99 %) or ticlopidine (approximately 1 %) according to national or local guidelines]. The higher dose of rivaroxaban (5 mg twice daily) did not form part of the marketing authorisation. A post hoc subgroup analysis of the licensed patients who had ACS with elevated cardiac biomarkers (that is, patients with STEMI and NSTEMI) without prior stroke or transient ischaemic stroke showed that compared with standard care, the addition of rivaroxaban (2.5 mg twice daily) to existing antiplatelet therapy reduced the composite endpoint of cardiovascular mortality, myocardial infarction or stroke, but increased the risk of major bleeding and intracranial haemorrhage. However, there were a number of limitations in the evidence base that warrant caution in its interpretation. In particular, the evidence may be confounded because of the post hoc subgroup analysis, modified intention-to-treat analyses, high dropout rates and missing vital status data. Results from the company's economic evaluation showed that the deterministic incremental cost-effectiveness ratio (ICER) for rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone compared with aspirin plus clopidogrel or aspirin alone was £6203 per quality-adjusted life-year (QALY) gained. In contrast, the ERG's preferred base case estimate was £5622 per QALY gained. The ICER did not rise above £10,000 per QALY gained in any of the sensitivity analyses undertaken by the ERG, although the inflexibility of the company's economic model precluded the ERG from formally undertaking all desired exploratory analyses. As such, only a crude exploration of the impact of additional bleeding events could be undertaken. The NICE Appraisal Committee concluded that the ICERs presented were all within the range that could be considered cost effective and that the results of the ERG's exploratory sensitivity and scenario analyses suggested that the ICER was unlikely to increase to the extent that it would become unacceptable. The Appraisal Committee therefore concluded that rivaroxaban in combination with aspirin plus clopidogrel, or with aspirin alone, was a cost-effective use of National Health Service (NHS) resources for preventing atherothrombotic events in people with ACS and elevated cardiac biomarkers